CN102532107A - 4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives, and preparation method and application thereof - Google Patents

4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives, and preparation method and application thereof Download PDF

Info

Publication number
CN102532107A
CN102532107A CN2010105963055A CN201010596305A CN102532107A CN 102532107 A CN102532107 A CN 102532107A CN 2010105963055 A CN2010105963055 A CN 2010105963055A CN 201010596305 A CN201010596305 A CN 201010596305A CN 102532107 A CN102532107 A CN 102532107A
Authority
CN
China
Prior art keywords
compound
general formula
quinazoline
derivatives
methoxyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2010105963055A
Other languages
Chinese (zh)
Other versions
CN102532107B (en
Inventor
李祎亮
蔡志强
刘巍
石玉
邹美香
汤立达
张士俊
商倩
孟凡翠
徐为人
李洪明
林木森
刘金雷
纪潇朗
范宗兄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Tiancheng New Drug Evaluation Co ltd
Original Assignee
Tianjin Institute of Pharmaceutical Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Institute of Pharmaceutical Research Co Ltd filed Critical Tianjin Institute of Pharmaceutical Research Co Ltd
Priority to CN201010596305.5A priority Critical patent/CN102532107B/en
Publication of CN102532107A publication Critical patent/CN102532107A/en
Application granted granted Critical
Publication of CN102532107B publication Critical patent/CN102532107B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to 4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives (shown as a general formula I), and a preparation method and application thereof. In the general formula, R1, R2 and n are respectively defined in the specifications. The invention also relates to a preparation method for the derivatives, physiologically acceptable salts formed by the derivatives and inorganic or organic acids, and medicinal compositions containing the derivatives and the salts. The compounds have valuable pharmacological properties, have an effect of inhibiting signal transduction caused by protein tyrosine kinase (PTK), particularly have high activity of inhibiting mutant epidermal growth factor receptor EGFR (L858R/T790M), and have low toxicity. The invention also relates to application of the derivatives in treatment of diseases, particularly tumor diseases, and a preparation method for the derivatives. The general formula I is shown in the specifications.

Description

4-substituted anilinic-high piperazinyl-the quinazoline derivant of 7-substituted alcoxyl
Technical field
The present invention relates to the synthetic field of medicine, be specifically related to the preparation method of 4-substituted anilinic-high piperazinyl-quinazoline derivant of 7-substituted alcoxyl.
Background technology
Tumour is a series of with abnormal cells hyperplasia out of control and the disease that is diffused as characteristic; It is the healthy major disease of serious threat human life; According to statistics, about more than 790 ten thousand people of annual global tumor mortality sum, China dies from tumour person more than 160 ten thousand people every year; And increase gradually, become first cause of the death of urban population.
Protein tyrosine kinase (PTK) is one type of enzyme that in normal cell growth, plays an important role, and it can be transferred on the residue of protein substrate from ATP by the catalysis phosphate group.Many EGF-R ELISAs (EGFR) albumen all has the effect of protein tyrosine kinase, and the interaction of these acceptors and growth factor also is that the growth of normal regulating cell is necessary.Yet the over-expresses of EGFR through the effect of himself Tyrosylprotein kinase, can cause the cell transition increment, finally causes the generation of tumour.
Based on the vital role that the receptor kinase of lacking of proper care is risen in cancer pathology, specific ptk inhibitor is the research focus of present carcinostatic agent as the exploitation of potential anticancer therapeutic agent.Therefore present many synthetic compounds all have the activity of inhibition epidermal growth factor recipient tyrosine kinase (EGFR-PTK); Especially the most deep with quinazoline compounds research; Wherein ZD1839 was used to treat nonsmall-cell lung cancer (Ranson in 2003 by FDA approval listing; M.Epideraml growth factor receptor tyrosine kinase inhibitors.British J.Cancer 2004,90,2250-2255.).ZD6474 had both had the activity that suppresses EGFR; Has the activity that suppresses VEGFR simultaneously; Declared listing (Alessandro, M.Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase:Current Status and Future DirectionsThe Oncologist 2009 in 2009; 14,378-390.).The verivate that WO 99/06378, WO 2000/31048 and WO2000/06555 (Chinese patent CN99808949) also relate to some substituted quinazoline has irreversible ptk inhibitor activity.
Traditional quinazoline derivant is in the disease that the treatment cell hyperplasia causes; Need a very big metering just can reach efficacious therapy; This tends to aggravate the spinoff such as dysentery and fash of its generation, need further study the medicine of seeking effective and low toxic side effect for this reason.
WO 97/30035 disclose quinazoline derivative ZD6474 with and as the application of ptk inhibitor.Experiment showed, that this compounds has good inhibitory effect to Human umbilical vein endothelial cells (HUVEC).
In China, high piperazine is mainly used in pharmaceutical industry, is that the pharmaceuticals of raw material have kind more than 20 with it.At present, the medicinal efficacy of the high bridged piperazine derivatives of external popular exploitation.Can be used as antiphlogistic with high some verivate of piperazine synthetic, the other verivate can lowering blood glucose, thereby to the treatment mellitus, obesity etc. have effect preferably.The seven membered heterocyclic of high piperazine is polygon ring, and their midbody majority has intensive biological activity and pharmaceutical use.The high piperazine of nitrogen-containing heterocycle compound is a medicine synthetic important intermediate.Contained dinitrogen atom can with many organic compound reactions, especially the structural modification of chemicals with transform in important role is arranged.Can effectively combine after the butt joint of high piperazine dinitrogen atom and quinazoline, the activity of tumour medicine is significantly improved with the tumour target.Simultaneously, compare with the ZD6474 analog derivative, comprise side chains such as piperidines and piperazine, high piperazine structure can improve the physical and chemical parameter of whole molecule preferably, improves its pharmacokinetic property, thereby the research of high piperazine series compound is more and more come into one's own.
Therefore; High piperazine and quinazoline parent nucleus are organically combined, the EGFR and the VEGFR2 of T790M and L858R sudden change shown high tolerance activity, and toxic side effect is lower; Obtained beyond thought action effect; Its external activity is ZD6474 more than ten times, to having broad application prospects as drug research, this shows it is synthesized and the research of verivate has practical value.
Summary of the invention
The purpose of this invention is to provide one type of novel 4-substituted anilinic-high piperazinyl-quinazoline derivant of 7-substituted alcoxyl, and this compounds in antitumor drug as the purposes of activeconstituents.
The present invention be quinazoline derivant shown in general formula (I):
Figure BDA0000039410310000031
General formula (I)
Wherein:
R1 representes: hydrogen, methoxyl group, preferably from methoxyl group;
R2 representes: hydrogen, methyl, ethyl, preferably from hydrogen and methyl;
N representes: 1 or 2 or 3 or 4, and preferably from 3.
Below be the preparation method of The compounds of this invention, wherein initial compounds (II) can be purchased.
Figure BDA0000039410310000041
Compound (II) prepares compound III with sulfur oxychloride through chlorination reaction, and compound III and 2-fluoro-4 bromo-aniline obtain compound IV through the azane glycosylation reaction; Compound IV debenzylation under three fluoro acetate conditions obtains V, and compound V obtains compound VI with the reaction of different halogenated alkane again, again with the high piperazine reaction of Boc-, take off Boc, the N-alkylation obtains general formula (I) target compound.
R wherein 1, R 2As above define with n.
The pharmacy acceptable salt of formula according to the invention (I) compound can contain carboxyl or amido according to different verivates, and carboxyl can react with alkaline matter (like oxyhydroxide, carbonate and the supercarbonate of basic metal or earth alkali metal); They include, but are not limited to: sodium hydroxide, Pottasium Hydroxide; Calcium hydroxide; Yellow soda ash etc. form pharmacy acceptable salt, like corresponding sodium salts, and sylvite or calcium salt or the like.Also can adopt nontoxic organic bases such as methylamine, triethylamine, meglumine etc. to generate salt; Amido can react with acidic substance (example hydrochloric acid, Hydrogen bromide, sulfuric acid etc.), and they include, but are not limited to: hydrochloric acid, and Hydrogen bromide, sulfuric acid, phosphoric acid etc. form pharmacy acceptable salt, also can adopt organic acid such as acetate, oxalic acid, Hydrocerol A etc. to generate salt.The compound of formula (I) and the form of salt thereof have anti-tumor activity,
Formula according to the invention (I) compound or its pharmacy acceptable salt can be processed pharmaceutical composition jointly with one or more pharmaceutically acceptable carriers, vehicle or thinner.This pharmaceutical composition can be processed formulations such as solid orally ingestible, liquid oral medicine, injection.
Said solid and liquid oral medicine comprise: tablet, dispersible tablet, enteric coated tablet, chewable tablet, oral cavity disintegration tablet, capsule, syrup, granule, oral solution.Can adopt lactose or starch carrier as said solid orally ingestible; Use gelatin, methylcellulose gum, hypromellose, Vinylpyrrolidone polymer, starch slurry etc. are as tackiness agent; Use starch, Xylo-Mucine, carboxymethylstach sodium, low-substituted hydroxypropyl methylcellulose, PVPP, Microcrystalline Cellulose as disintegrating agent; Use talcum powder, little part of silica gel, stearin, calcium stearate or magnesium etc. are as antiadhesives and lubricant.The preparation method of said solid orally ingestible may further comprise the steps: with activeconstituents and carrier and optionally with a disintegration additive composition mixture; Make the aqs soln of this mixture and tackiness agent then; Alcohol property or aqueous alcohol property solution carry out wet method or dry granulation in suitable device; Dried particles, the disintegrating agent, lubricant and the antisticking agent that add other are subsequently processed appropriate formulations.
Said injection comprises: little pin, freeze-dried powder and infusion solutions etc.The preparation method of said injection may further comprise the steps: get water for injection, the auxiliary material that takes by weighing recipe quantity stirs and makes dissolving, adds the sample stirring and dissolving; Adjust pH is to proper range; After adding the charcoal absorption certain hour of 0.1%-0.5%, decarburization, filtration, packing or freeze-drying again.
The present invention shows through vitro homogeneous time-resolved fluorescence method (HTRF) test: the quinazoline derivant with general formula I structure has very strong restraining effect to EGFR (L858R/T790M) and VEGFR-2; Test shows that this type of toxicity of compound is lower to mouse body inner model simultaneously.
Embodiment
Following embodiment can make those skilled in the art more comprehensively understand the present invention, but does not limit the present invention in any way.
The preparation of embodiment 17-(3-(1,4-Diazesuberane-1-yl) propoxy-)-N-(4-bromo-2-fluorophenyl)-6-methoxyl group quinazoline-4-amine (VIII)
The first step: (5.0g 0.018mol) is dissolved among the DMF (20mL), drips thionyl chloride, reflux 3h with 7-benzyloxy-6-methoxyl group quinazoline-4-one.Steaming desolventizes, and re-crystallizing in ethyl acetate obtains white solid 7-benzyloxy-4-chloro-6-methoxyl group quinazoline (4.8g, 90.2%), m.p.247 ℃; 1H NMR (400MHz, DMSO): δ 3.84 (s, 3H, CH 3O), 5.26 (s, 2H, CH 2O), 7.23 (s, 1H, ArH), 7.41-7.55 (m, 7H, ArH), 7.99 (s, 1H, Ar) .ESI-MS:m/z 301 [M+H] +.
Second step: (4.8g, 0.016mol) (3.0g 0.016mol) is dissolved in the Virahol (100mL) reflux 2h with 2-fluoro-4-bromo-aniline with 7-benzyloxy-4-chloro-6-methoxyl group quinazoline.After the solution cooling, filter, Virahol and ether are washed, dry 7-benzyloxy-N-(2-bromo-4-fluorophenyl)-6-methoxyl group quinazoline-4-amine (6.9g, 95.8%), m.p.231-233 ℃ of getting; 1HNMR (400MHz, DMSO): δ 3.99 (s, 3H, CH 3O), 5.26 (s, 2H, CH 2O), 7.38-7.50 (m, 10H, ArH), 8.13 (s, 1H, Ar), 8.77 (s, 1H, Ar) .ESI-MS:m/z455 [M+H] +.
The 3rd step: (6.9g 0.015mol) is dissolved in the three fluoro acetic acid of 50mL reflux 1h with 7-benzyloxy-N-(4-bromo-2-fluorophenyl)-6-methoxyl group quinazoline-4-amine.After the cooling, mixture is poured in the trash ice, filters, and solid is dissolved in the methyl alcohol; Using ammoniacal liquor to regulate pH is 11, concentrates after-filtration, and ether is washed, vacuum-drying; Obtain white solid 4-(4-bromo-2-fluoroaniline)-6-methoxyl group quinazoline-7-phenol (4.9g, 88.6%), m.p.145-147 ℃; 1H NMR (400MHz, DMSO): δ 3.94 (s, 3H, CH 3O), 7.33-7.55 (m, 4H, ArH), 7.56-7.88 (m, 2H, ArH), 8.11 (s, 1H, Ar), 8.67 (s, 1H, Ar) .ESI-MS:m/z 364 [M+H] +.
The 4th the step: with 4-(4-bromo-2-fluoroaniline)-6-methoxyl group quinazoline-7-phenol (4.9g, 0.013mol), 3-bromine n-propyl chloride (2.0g, 0.013mol), salt of wormwood (3.7g, 0.026mol) with 100mL DMF be heated to 60 ℃ the reaction 10h.Solvent evaporated, bullion column chromatography (ETHYLE ACETATE: sherwood oil=4: 1) obtain white solid N-(4-bromo-2-fluoroanilino)-7-(3-chloropropane base)-6-methoxyl group quinazoline-4 amine 5.0g, yield 71.0%, m.p.134-136 ℃; 1HNMR (400MHz, DMSO): δ 1.22-1.65 (m, 2H, CH 2), 1.98-1.2.01 (m, 2H, CH 2), 2.38-2.55 (m, 2H, CH 2), 3.94 (s, 3H, CH 3O), 7.33-7.55 (m, 4H, ArH), 8.11 (s, 1H, Ar), 8.67 (s, 1H, Ar), 8.77 (s, 1H, Ar) .ESI-MS:m/z 440 [M+H] +
The 5th step: with 5.0g (11.36mmol) N-(4-bromo-2-fluoroanilino)-7-(3-chloropropane base)-6-methoxyl group quinazoline-4 amine and high piperazine of 2.8g (140mmol) N-BOC-, be dissolved among the 70mlDMA, add salt of wormwood 4.7g (34.08mmol); Be warming up to 70 ℃ of reaction 3h, the TLC detection reaction finishes, and is cooled to room temperature; Reaction solution is poured in the frozen water, had yellow solid to separate out, filter; The washing filter cake, drying, re-crystallizing in ethyl acetate get the yellow solid tertiary butyl-4-(3-((4-((4 bromo-2-fluorophenyl) amino)-6-methoxyl group quinazoline-7-yl) oxygen base) propyl group)-1; 4-Diazesuberane-1-carboxylicesters 5.49g, productive rate 80%, m.p.154-155 ℃; 1H NMR (400MHz, DMSO): δ 1.05 (s, 9H, 3 * CH 3), 1.22-1.65 (m, 2H, CH 2), 1.98-2.01 (m, 2H, CH 2), 2.38-2.55 (m, 2H, CH 2), 2.71-3.42 (m, 10H, 5 * CH 2), 3.94 (s, 3H, CH 3O), 7.33-7.55 (m, 4H, ArH), 8.11 (s, 1H, Ar), 8.67 (s, 1H, Ar), 8.77 (s, 1H, Ar) .ESI-MS:m/z 604 [M+H] +
The 6th step: with 5.0g (8.28mmol) tertiary butyl-4-(3-((4-((4 bromo-2-fluorophenyl) amino)-6-methoxyl group quinazoline-7-yl) oxygen base) propyl group)-1,4-Diazesuberane-1-carboxylicesters drops in the reaction flask, adds the 60ml methylene dichloride, is partly dissolved; Stir adding 60ml trifluoroacetic acid down, reaction solution is clarified fully, and the reaction solution color becomes brown; Stirring at room reaction 1h, the TLC detection reaction is complete, and decompression steams trifluoroacetic acid; Wash 2 times with a small amount of ether, discard ether layer, water layer is transferred pH to 10 with 2M sodium hydroxide; Which floor dichloromethane extraction is associated with, anhydrous magnesium sulfate drying; Filter, the evaporated under reduced pressure methylene dichloride obtains yellow solid, and (3-(1 to obtain yellow solid 7-with re-crystallizing in ethyl acetate; 4-Diazesuberane-1-yl) propoxy-)-and N-(4-bromo-2-fluorophenyl)-6-methoxyl group quinazoline-4-amine (VIII) 3.75g, productive rate 90%, m.p.177-179 ℃; 1H NMR (400MHz, DMSO): δ 1.22-1.65 (m, 2H, CH 2), 1.98-2.01 (m, 2H, CH 2), 2.08-2.09 (m, 1H, NH), 2.38-2.55 (m, 2H, CH 2), 2.71-3.42 (m, 10H, 5 * CH 2), 3.94 (s, 3H, CH 3O), 7.33-7.55 (m, 4H, ArH), 8.11 (s, 1H, Ar), 8.67 (s, 1H, Ar), 8.77 (s, 1H, Ar) .ESI-MS:m/z 504 [M+H] +
The preparation of embodiment 2N-(4-bromo-2-fluorophenyl)-6-methoxyl group-7-(3-(4-methyl isophthalic acid, 4-Diazesuberane-1-yl) propoxy-) quinazoline-4-amine (I-1)
1.0g (3.96mmol) 7-(3-(1,4-Diazesuberane-1-yl) propoxy-)-N-(4-bromo-2-fluorophenyl)-6-methoxyl group quinazoline-4-amine solvent in 20ml formic acid, is added 10ml37% formaldehyde under the stirring at room, it is brown finishing reaction solution; Be warmed up to 95 ℃ of reaction 4h, the TLC detection reaction finishes, and decompression steams unreacted formic acid and formaldehyde, is dissolved in water; Water layer is transferred pH=11 with 2M sodium hydroxide, and water layer is used ethyl acetate extraction, merges organic layer; Anhydrous magnesium sulfate drying filters, and mother liquor is directly mixed appearance; Preparative column separation and purification (ethyl acetate/methanol=10: 1) fast obtains yellow solid N-(4-bromo-2-fluorophenyl)-6-methoxyl group-7-(3-(4-methyl isophthalic acid, 4-Diazesuberane-1-yl) propoxy-) quinazoline-4-amine (I-1) 1.64g; Productive rate 80%,, m.p.166-167 ℃; 1H NMR (400MHz, DMSO): δ 1.22-1.65 (m, 2H, CH 2), 1.98-2.01 (m, 2H, CH 2), 2.23 (S, 3H, CH 3N), 2.38-2.55 (m, 2H, CH 2), 2.71-3.42 (m, 10H, 5 * CH 2), 3.94 (s, 3H, CH 3O), 7.33-7.55 (m, 4H, ArH), 8.11 (s, 1H, Ar), 8.67 (s, 1H, Ar), 8.77 (s, 1H, Ar) .ESI-MS:m/z 518 [M+H] +
Embodiment 3
Method for preparing tablet thereof is following:
Prescription consumption/sheet
I-1 100mg
Microcrystalline Cellulose 50mg
Starch 40mg
Polyvidone 8mg
Sodium starch glycolate 10mg
Magnesium Stearate qs
Technology: the activeconstituents auxiliary material is crossed 100 mesh sieves respectively, take by weighing the main ingredient and auxiliary material (half sodium starch glycolate) thorough mixing of recipe quantity, add the Vinylpyrrolidone polymer aqueous solution and make softwood in right amount; Cross 24 mesh sieves; Make wet granular in 50-60 ℃ of baking oven dry about 2-3 hour, will remain sodium starch glycolate and Magnesium Stearate and particle and mix, whole; Measure midbody content, with the shallow stamping of Φ 8mm.
Embodiment 4
The preparation of injection liquid
I-3 200mg
SODIUM PHOSPHATE, MONOBASIC 10mg
Hydrocerol A 30mg
Water for injection 50ml
Technology: get water for injection 50ml, the Hydrocerol A, the SODIUM PHOSPHATE, MONOBASIC that take by weighing recipe quantity stir and make dissolving, add the sample stirring and dissolving, use the hydrochloric acid of 0.1mol/L or sodium hydroxide adjust pH to be 4.0-5.0, the charcoal absorption of adding 0.1% 20 minutes.Filter with 0.45 μ m filter membrane earlier, again with the smart filter of 0.22 μ m.Press 5 milliliters of cans of per ampoule, 105 ℃ of high-temperature sterilizations promptly got injection liquid in 30 minutes.
The anxious poison test of mouse in the extracorporeal anti-tumor enzymic activity test of compound VIII and I-1 and the body
One, extracorporeal anti-tumor enzymic activity test
(1) material and instrument:
1 experiment material: the test kit HTRF KinEASE-TK kit of Cisbio company (article No.: 62TKOPEB); Distilled water
2 detecting instruments: SpectraMax M5:Mplecular Devices product
(2) testing sequence:
1. the preparation of solution and reaction density
Figure BDA0000039410310000111
2. experimental procedure:
1) calculates all ingredients institute expense.
2) prepare the working fluid of ATP, TK Substrate-biotin.
3) ratio ATP by volume: TK Substrate-biotin: Kinase buffer=2: after getting the liquid mixing at 2: 1, get mixed solution to the BP pipe by 5 μ L/ holes.
4) add medicine, 2 μ L/ holes.No medicine hole is with 2 μ L kinase buffer polishings.Mixing.
5) prepare the working fluid of enzyme.
6) add enzyme, 3 μ L/ holes.No enzyme hole is with 3 μ L kinase buffer polishings.Mixing.
7) reaction solution is transferred in 384 orifice plates.
8) put 37 ℃ of incubation 30min.
9) working fluid of preparation Streptavidin-XL665 calculates consumption, by volume ratio Streptavidin-XL665: TK Antibody-Cryptate=1: 1 mixing.Incubation is got mixed solution by 10 μ L/ holes and is added in the reaction system after finishing, and mixing is with termination reaction.
10) room temperature is placed the 30min detection, excites in the single wavelength of ELIASA 314nm, measures 620nm and 665nm emission light, and test-results is seen table 1 and table 2.
Inhibiting rate (%)=[1-(experimental group 665nm/620nm-blank control group 665nm/620nm)/(control group 665nm/620nm-blank control group 665nm/620nm)] * 100%.The Bliss method is calculated test-compound IC 50Value.
3. result
The inhibiting rate (%) of table 1. couple EGFR (L858R/T790M) and VEGFR-2
Figure BDA0000039410310000121
The IC of table 2. couple EGFR (L858R/T790M) and VEGFR-2 50(nM)
Figure BDA0000039410310000131
Two, the anxious poison test of mouse in the body
Laboratory animal: Kunming mouse (male and female half and half)
Experimental technique:
1. test last late fasting 12 hours;
2. mouse random packet, male and female half and half are weighed in;
3. mouse is provided with 2-3 dose groups administration, and medicine is weighed, and adds tween-80 and grinds the 1%CMC-Na dissolved dilution;
4. every mouse 0.5mL oral administration (ig);
5. observe mouse administration afterreaction; Record toxicity symptom, time length and recovery situation; As death appears, then write down death time of animal and dead preceding symptom etc.;
6. dead mouse is dissected inspection, the record anatomical results;
7. observed weighing every day mouse body weight, record changes of weight situation continuously 7 days;
8. obtain medium lethal dose(LD&-{50}) (LD50) or maximum tolerated dose (MTD).
Figure BDA0000039410310000132
Figure BDA0000039410310000141

Claims (8)

1. general formula (I) quinazoline derivant or its pharmacy acceptable salt:
General formula (I)
Wherein:
R1 representes: hydrogen, methoxyl group;
R2 representes: hydrogen, methyl, ethyl;
N representes: 1, or 2, or 3, or 4.
2. compound according to claim 1 is characterized in that R1 is preferably from methoxyl group.
3. compound according to claim 1 is characterized in that R2 is preferably from hydrogen and methyl.
4. compound according to claim 1 is characterized in that n is preferably from 3.
5. pharmaceutically can connect according to the defined general formula of claim 1-4 (I) compound or its
The salt that receives, said compound or its pharmacy acceptable salt are selected from,
N-(4-bromo-2-fluorophenyl)-6-methoxyl group-7-(3-(4-methyl isophthalic acid, 4-Diazesuberane-1-yl) propoxy-) quinazoline-4-amine
7-(3-(1,4-Diazesuberane-1-yl) propoxy-)-N-(4-bromo-2-fluorophenyl)-6-methoxyl group quinazoline-4-amine.
6. according to the described compound of claim 1-5, it is characterized in that its corresponding medicinal salt is: formula 1 compound H qX, X represents halogen, sulfate radical, nitrate radical, phosphate radical, organic acid, q are 1, or 2, or 3.
According to the described arbitrary compound of claim 1-6 as antitumor drug or as the purposes of the activeconstituents in the anti-tumor composition.
8. pharmaceutical composition contains the defined general formula of claim 1 (I) compound or its pharmacy acceptable salt and the appropriate carriers or the vehicle of pharmacy effective dose.
The described compound of claim 1-8 or its pharmacy acceptable salt, wherein, described compound or its pharmacy acceptable salt comprise various solid orally ingestibles, liquid oral medicine, injection.
CN201010596305.5A 2010-12-20 2010-12-20 4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives, and preparation method and application thereof Expired - Fee Related CN102532107B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201010596305.5A CN102532107B (en) 2010-12-20 2010-12-20 4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives, and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201010596305.5A CN102532107B (en) 2010-12-20 2010-12-20 4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives, and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN102532107A true CN102532107A (en) 2012-07-04
CN102532107B CN102532107B (en) 2014-03-12

Family

ID=46340280

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201010596305.5A Expired - Fee Related CN102532107B (en) 2010-12-20 2010-12-20 4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives, and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN102532107B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023330A1 (en) * 2014-08-11 2016-02-18 石药集团中奇制药技术(石家庄)有限公司 Quinazoline derivative
CN111909163A (en) * 2020-04-21 2020-11-10 南开大学 Quinolamine compound with IDO1 inhibition function and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019774A1 (en) * 1994-01-25 1995-07-27 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
CN1116286C (en) * 1996-03-05 2003-07-30 曾尼卡有限公司 4-anilinoquinazoline derivatives
WO2007068552A1 (en) * 2005-12-12 2007-06-21 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019774A1 (en) * 1994-01-25 1995-07-27 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
CN1116286C (en) * 1996-03-05 2003-07-30 曾尼卡有限公司 4-anilinoquinazoline derivatives
WO2007068552A1 (en) * 2005-12-12 2007-06-21 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023330A1 (en) * 2014-08-11 2016-02-18 石药集团中奇制药技术(石家庄)有限公司 Quinazoline derivative
CN106660970A (en) * 2014-08-11 2017-05-10 石药集团中奇制药技术(石家庄)有限公司 Quinazoline derivative
JP2017526668A (en) * 2014-08-11 2017-09-14 石薬集団中奇制薬技術(石家庄)有限公司 Quinazoline derivatives
US10421754B2 (en) 2014-08-11 2019-09-24 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Quinazoline derivative
RU2704125C2 (en) * 2014-08-11 2019-10-24 СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКАЛ ТЕКНОЛОДЖИ (ШИЦЗЯЧЖУАН) КО., ЛТД. Quinazoline derivatives
CN106660970B (en) * 2014-08-11 2020-07-10 石药集团中奇制药技术(石家庄)有限公司 Quinazoline derivatives
US10774079B2 (en) 2014-08-11 2020-09-15 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Quinazoline derivative
CN111909163A (en) * 2020-04-21 2020-11-10 南开大学 Quinolamine compound with IDO1 inhibition function and preparation method thereof

Also Published As

Publication number Publication date
CN102532107B (en) 2014-03-12

Similar Documents

Publication Publication Date Title
KR100658891B1 (en) Quinazoline derivatives inhibiting the growth of cancer cell and preparation thereof
CN102464658B (en) Oxazolidinone derivative and preparation method and application thereof
JP5268902B2 (en) Salt of pyrrolopyrimidinone derivative and process for producing the same
CN102295635B (en) Antitumor medicament tetralin amide compounds and pharmaceutically acceptable salts thereof as well as preparation method and application of antitumor medicament tetralin amide compounds
EP2985283B1 (en) Anti-angiogenesis compound, intermediate and use thereof
KR20080003599A (en) Gentisate of pyrrolopyrimidinone derivative and process for preparing it
EP0991627B1 (en) Pyrimidinone compounds, pharmaceutical compositions containing the compounds and the process for preparing the same
BRPI0609962B1 (en) ORAL PHARMACEUTICAL COMPOSITION
CN102485724B (en) Substituted thiophene base pyrazolo-pyridines and medicinal use thereof
CN101575333A (en) Quinazoline derivatives and medical application thereof
CN104250253B (en) Substituted-tetrahydro naphthoyl aminated compounds and its pharmaceutically acceptable salt and preparation method and application
CN113307791B (en) Pyrimidylpiperazine urea TRPV1 antagonistic/MOR agonistic double-target compound and preparation method and application thereof
CN102532107B (en) 4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives, and preparation method and application thereof
KR20140036312A (en) Novel compound having parp inhibitory activity
CN102532103B (en) Quinazolinyl aryl urea derivatives and preparation method and application thereof
CN102268000A (en) Novel spiroheterocyclic compound and application of same serving as therapeutic agent
CN102101858B (en) Preparation method of ramosetron derivatives and applications thereof
CN107513040A (en) Substitute the preparation of benzo pyridine compound and the application of molecular targeted anti-tumor medicine
WO2019001307A1 (en) Amide compound, composition containing same, and use thereof
CN101659659B (en) Pyridine derivative and medical application thereof
CN102060875B (en) Quinazoline derivative, and preparation method and application thereof
CN110204493A (en) Tricyclic antidepressants XOR inhibitor and its preparation method and application
CN102617465A (en) Tacrine-caffeic acid hetero-blends, their preparation method and medicinal compositions
CN103626722A (en) Hypoglycemic compound of nitric oxide donor type, preparation method and purpose thereof
CN108299397B (en) A kind of active medicine and preparation method thereof for blood pressure lowering

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 300193 Anshan West Road, Nankai District, Nankai District, Tianjin

Patentee after: Tianjin Institute of Pharmaceutical Research Co.,Ltd.

Address before: 300193 Anshan West Road, Nankai District, Nankai District, Tianjin

Patentee before: Tianjin Institute of Pharmaceutical Research

TR01 Transfer of patent right

Effective date of registration: 20190220

Address after: 300301 No. 308 Huiren Road, Binhai Science Park, Tianjin Binhai High-tech Zone

Patentee after: NEW DRUGS EVALUATE Co.,Ltd. TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH

Address before: 300193 Anshan West Road, Nankai District, Nankai District, Tianjin

Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd.

TR01 Transfer of patent right
CP03 Change of name, title or address

Address after: 300301 No. 308, Huiren Road, Binhai Science Park, Binhai high tech Zone, Binhai New Area, Tianjin

Patentee after: Tianjin Tiancheng new drug evaluation Co.,Ltd.

Address before: 300301 No. 308 Huiren Road, Binhai Science Park, Tianjin Binhai High-tech Zone

Patentee before: NEW DRUGS EVALUATE Co.,Ltd. TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH

CP03 Change of name, title or address
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140312

CF01 Termination of patent right due to non-payment of annual fee